Immunogenicity and safety of the human rotavirus vaccine Rotarix™ co-administered with routine infant vaccines following the vaccination schedules in Europe

Vaccine

Volumn 28, Issue 32, 2010, Pages 5272-5279

  Vesikari, Timo ^a   Karvonen, Aino ^a   Prymula, Roman ^b   Schuster, Volker ^c   Tejedor, Juan C ^d   Thollot, Franck ^e   Garcia Corbeira, Pilar ^f   Damaso, Silvia ^f   Han, Htay Htay ^f   Bouckenooghe, Alain ^f  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b UNIVERSITY OF DEFENCE   (Czech Republic)

^c UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^d HOSPITAL DE MÓSTOLES   (Spain)

^e Medical Facility   (France)

^f GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Concomitant administration; Immune response; Rotavirus; Safety; Vaccination

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HEPATITIS B VACCINE; IMMUNOGLOBULIN A ANTIBODY; INFANRIX QUINTA; MENINGOCOCCUS VACCINE; PLACEBO; PNEUMOCOCCUS VACCINE; ROTAVIRUS VACCINE; UNCLASSIFIED DRUG; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS VACCINE; HEPATITIS B VACCINE; HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE; IMMUNOGLOBULIN A; LIVE VACCINE; POLIOMYELITIS VACCINE; RIX4414 VACCINE; VACCINE; VIRUS ANTIBODY;

ANOREXIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CZECH REPUBLIC; DIARRHEA; DIPHTHERIA; DRUG FATALITY; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; EPILEPSY; EUROPE; FEMALE; FINLAND; FRANCE; GERMANY; HAEMOPHILUS INFECTION; HAEMOPHILUS INFLUENZAE; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFANT; INFANTILE SPASM; INTUSSUSCEPTION; IRRITABILITY; ITALY; MAJOR CLINICAL STUDY; MALE; MENINGOCOCCOSIS; MILLER DIEKER SYNDROME; MULTICENTER STUDY; PERTUSSIS; PHASE 3 CLINICAL TRIAL; PNEUMOCOCCAL INFECTION; POLIOMYELITIS; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; ROTAVIRUS INFECTION; SEIZURE; SEROCONVERSION; SIDE EFFECT; SPAIN; TETANUS; UNSPECIFIED SIDE EFFECT; VACCINATION; VOMITING; BLOOD; DOUBLE BLIND PROCEDURE; IMMUNIZATION; IMMUNOLOGY;

ANTIBODIES, VIRAL; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; DOUBLE-BLIND METHOD; EUROPE; HAEMOPHILUS VACCINES; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION SCHEDULE; IMMUNOGLOBULIN A; INFANT; PNEUMOCOCCAL VACCINES; POLIOVIRUS VACCINE, INACTIVATED; ROTAVIRUS VACCINES; VACCINES, ATTENUATED; VACCINES, COMBINED;

EID: 77954958588     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.05.057     Document Type: Article

References (25)

1. Parashar U.D., Gibson C.J., Bresee J.S., Glass R.I. Rotavirus and severe childhood diarrhea. Emerg Infect Dis 2006, 12:304-306.
2. The Pediatric ROTavirus European CommitTee (PROTECT). The pediatric burden of rotavirus disease in Europe. Epidemiol Infect 2006; 134:908-16.
3. Soriano-Gabarró M., Mrukowicz J., Vesikari T., Verstraten T. Burden of rotavirus disease in European Union countries. Pediatr Infect Dis J 2006, 25:S7-S11.
4. Gil A., Carrasco P., Jiménez R., San-Martín M., Oyagüez I., Gonzáles A. Burden of hospitalizations attributable to rotavirus infection in children in Spain, period 1999-2000. Vaccine 2004, 22:2221-2225.
5. Vesikari T., Rautanen T., Von Bonsdorff C.-H. Rotavirus gastroenteritis in Finland: burden of disease and epidemiological features. Acta Paediatr 1999, 426:24-30.
6. Harris J.P., Jit M., Cooper D., Edmunds W.J. Evaluating rotavirus vaccination in England and Wales Part I. Estimating the burden of disease. Vaccine 2007, 25:3962-3970.
7. Jit M., Edmunds W.J. Evaluating rotavirus vaccination in England and Wales Part II. The potential cost-effectiveness of vaccination. Vaccine 2007, 25:3971-3979.
8. Jit M., Bilcke J., Mangen M.J.J., Salo H., Melliez H., et al. The cost-effectiveness of rotavirus vaccination: comparative analyses for five European countries and transferability in Europe. Vaccine 2009, 27:6121-6128.
9. Bernstein D.I., Smith V.E., Sherwood J.R., Schiff G.M., Sander D.S., DeFeudis D., et al. Safety and immunogenicity of a live attenuated human rotavirus 89-12 vaccine. Vaccine 1998, 16:381-387.
10. Bernstein D.I., Sack D.A., Rothstein E., Reisinger K., Smith V.E., O'Sullivan D., et al. Efficacy of live attenuated human rotavirus vaccine 89-12 in infants. Lancet 1999, 354:287-290.
11. Bernstein D.I., Sack D.A., Reisinger K., Rothstein E., Ward R.L. Second year follow-up evaluation of live attenuated human rotavirus vaccine 89-12 in healthy infants. J Infect Dis 2002, 186:1487-1489.
12. Vesikari T., Karvonen A., Korhonen T., Espo M., Lebacq E., Forster J., et al. Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants. Vaccine 2004, 22:2836-2842.
13. Vesikari T., Karvonen A., Puustinen L., Zeng S., Szakal E.D., Delem A., et al. Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatr Infect Dis J 2004, 23:937-943.
14. Phua K.B., Quak S.H., Lee B.W., Emmanuel S.C., Goh P., Han H.H., et al. Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants. J Infect Dis 2005, 192:S6-16.
15. Dennehy P.H., Brady R.C., Halperin S.A., Ward R.L., Alvey J.C., Fischer F.H., et al. Comparative evaluation of safety and immunogenicity of two doses of an oral live attenuated human rotavirus vaccine. Pediatr Infect Dis J 2005, 24:481-488.
16. Salinas B., Pérez Schael I., Linhares A.C., Ruiz Palacios G.M., Guerrero M.L., Yarzábal J.P., et al. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine RIX4414: a randomized, placebo-controlled trial in Latin American infants. Pediatr Infect Dis J 2005, 24:807-816.
17. Dennehy P.H., Bertrand H.R., Silas P.E., Damaso S., Friedland L.R., Abu-Elyazeed R. Co-administration of RIX4414 oral human rotavirus vaccine does not impact the immune response of antigens contained in routine infant vaccines in the United States. Pediatrics 2008, 122:e1062-e1066.
18. Vesikari T., Karvonen A., Prymula R., Schuster V., Tejedor J.C., Cohen R., et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomized, double-blind controlled study. Lancet 2007, 370:1757-1763.
19. Ruiz-Palacios G.M., Pérez-Schael I., Velázquez F.R., Abate H., Breuer T., Clemens S.C., et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006, 354:11-22.
20. Ward R.L., Bernstein D.I., Shukla R., Young E.C., Sherwood J.R., McNeal M.M., et al. Effect of antibodies to rotavirus on protection of adults challenged with human rotavirus. J Infect Dis 1989, 159:79-88.
21. World Health Organization (WHO/V&B/02,19), Vaccines and Biologicals. Acute intussusception in infants and children. Incidence, clinical presentation and management: a global perspective; 2002 http://www.who.int/vaccines-documents/.
22. Murphy T.V., Gargiullo P.M., Massoudi M.S., Nelson D.B., Jumaan A.O., Okoro C.A., et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 2001, 344:564-572.
23. Chang E., Zangwill K.M., Lee H., Ward J.I. Lack of association between rotavirus infection and intussusception: implications for use of attenuated rotavirus vaccines. Pediatr Infect Dis J 2002, 21:97-102.
24. Simonsen L., Viboud C., Elixhauser A., Taylor R.J., Kapikian A.Z. More on RotaShield and intussusception: the role of age at the time of vaccination. J Infect Dis 2005, 192:S36-S43.
25. Vesikari T., Matson D.O., Dennehy P., Van Damme P., Santosham M., Rodriguez Z., et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006, 354:23-33.